Evidence map›Paper›PMID 41600772›Full record

ReviewViruses2025

PROs Assessment in Dual (Either Oral or Injectable) Antiretroviral Regimen in People with HIV: A Narrative Review.

Maria Mazzitelli, Olivia Bargiacchi, Maria Aurora Carleo, Andrea Giacomelli, Camilla Muccini, Lucia Taramasso, Marcello Trizzino, Antonella Cingolani

Abstract readReview
In one paragraph

Review in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maria MazzitelliDipartimento di Sicurezza e Bioetica, Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.ORCID 0000-0003-0263-0703
Olivia BargiacchiInfectious and Tropical Diseases Unit, Ospedale Maggiore della Carità, 28100 Novara, Italy.ORCID 0009-0001-3405-8273
Maria Aurora CarleoInfectious Diseases and Gender Medicine Unit, Cotugno Hospital, 80131 Napoli, Italy.
Andrea GiacomelliDepartment of Biomedical Sciences, Milan University, 20122 Milan, Italy.ORCID 0000-0003-3685-4289
Camilla MucciniInfectious Diseases Unit, Ospedale San Raffaele IRCSS, 20132 Milano, Italy.
Lucia TaramassoInfectious and Tropical Diseases Unit, Ospedale San Martino, 16131 Genova, Italy.ORCID 0000-0002-6622-6358
Marcello TrizzinoInfectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Policlinico Giaccone, 90127 Palermo, Italy.ORCID 0000-0002-8105-5139
Antonella CingolaniDipartimento di Sicurezza e Bioetica, Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.ORCID 0000-0002-3793-2755

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith modern antiretroviral regimens, durable viral suppression is now achieved in most people with HIV (PWH), whose life expectancy approaches that of the general population. Consequently, recent guidelines emphasise, beyond virological and immunological control, health-related quality of life and patient-reported outcomes (PROs) as targets of HIV care, including for dual regimens.

methodsWe conducted a narrative review of clinical trials and observational studies evaluating PROs in adults treated with dual antiretroviral therapies, either oral or long-acting injectable. We also examined guideline documents and implementation studies addressing the role, feasibility, and interpretation of PROs in routine HIV care.

resultsTrials of dual regimens reported high treatment satisfaction, convenience, and stable or improved quality of life, with some concerns related to injection-site reactions and visit burden for long-acting formulations. Emerging real-world data broadly confirm these findings but remain heterogeneous, with variability in instruments, assessment timing, and analytic approaches, limiting comparability and clinical use.

conclusionsPROs may support shared decision-making and optimise the use of dual therapies in PWH, but their uptake in clinical practice is still limited. Standardised tools, clearer interpretative frameworks, and pragmatic implementation strategies are needed to better integrate PROs into everyday HIV care.

Indexed as

Anti-HIV AgentsHIV InfectionsPatient Reported Outcome MeasuresAdministration, OralAntiretroviral Therapy, Highly ActiveClinical Trials as TopicHumansInjectionsQuality of LifeAnti-HIV AgentsHIVinjectablespatient-reported outcomespeople with HIVPROstwo-drug regimens

Identifiers

PMID41600772
PMCPMC12846361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.